New Drug Review: SpravatoByShyam Patel, PharmD,Lisa M. Holle, PharmD, BCOP, FHOPAJune 13th 2019Both responder and remitter patients experienced a statistically significant longer time to relapse with esketamine compared to the placebo
What Pharmacists Need to Know About LofexidineByKevin W. Chamberlin, PharmD,Shyam Patel, PharmDOctober 1st 2018FDA approves lofexidine for opioid withdrawal symptoms.